Ascendiant Capital Markets Cuts AIM ImmunoTech (NYSE:AIM) Price Target to $4.50

AIM ImmunoTech (NYSE:AIM) had its target price lowered by Ascendiant Capital Markets from $5.00 to $4.50 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Separately, Maxim Group reduced their price objective on shares of AIM ImmunoTech from $2.00 to $1.00 and set a “buy” rating for the company in a research report on Tuesday, October 22nd.

AIM ImmunoTech Stock Down 3.5 %

AIM stock opened at $0.21 on Tuesday. The business has a 50-day moving average of $0.24 and a 200-day moving average of $0.31. AIM ImmunoTech has a fifty-two week low of $0.16 and a fifty-two week high of $0.62. The stock has a market capitalization of $13.41 million, a P/E ratio of -0.46 and a beta of -0.36. The company has a debt-to-equity ratio of 0.05, a current ratio of 0.75 and a quick ratio of 0.75.

Hedge Funds Weigh In On AIM ImmunoTech

An institutional investor recently bought a new position in AIM ImmunoTech stock. Armistice Capital LLC acquired a new stake in shares of AIM ImmunoTech Inc. (NYSE:AIM) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned 7.92% of AIM ImmunoTech at the end of the most recent quarter. 12.02% of the stock is currently owned by institutional investors.

AIM ImmunoTech Company Profile

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).